Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Revenues:
Total revenues	$ 54,759	$ 47,334	$ 114,310	$ 83,932
Cost of revenues:
Total cost of revenues	28,601	15,999	57,028	33,707
Gross profit	26,158	31,335	57,282	50,225
Operating expenses:
Research and development	43,138	50,835	88,982	101,446
Sales and marketing	10,734	9,693	21,101	19,864
General and administrative	25,189	23,536	50,991	49,077
Total operating expenses	79,061	84,064	161,074	170,387
Loss from operations	(52,903)	(52,729)	(103,792)	(120,162)
Other income (expense):
Gain on equity investments	0	0	0	0
Change in fair value of equity investments	4,579	(5,833)	(8,516)	2,304
Other income	5,438	4,598	9,642	9,626
Total other income (expense)	10,017	(1,235)	1,126	11,930
Loss before income taxes	(42,886)	(53,964)	(102,666)	(108,232)
Income tax expense	287	83	315	539
Net loss	$ (43,173)	$ (54,047)	$ (102,981)	$ (108,771)
Earnings Per Share [Abstract]
Net loss per share of common and limited common stockholders, basic (in USD per share)	$ (0.59)	$ (0.74)	$ (1.41)	$ (1.50)
Net loss per share of common and limited common stockholders, diluted (in USD per share)	$ (0.59)	$ (0.74)	$ (1.41)	$ (1.50)
Weighted average shares used to compute net loss per share of common and limited common stockholders, basic (in shares)	73,427,635	72,711,685	73,243,797	72,501,409
Weighted average shares used to compute net loss per share of common and limited common stockholders, diluted (in shares)	73,427,635	72,711,685	73,243,797	72,501,409
Software products and services
Revenues:
Total revenues	$ 40,544	$ 35,404	$ 89,360	$ 68,819
Cost of revenues:
Total cost of revenues	13,029	7,167	26,551	15,143
Drug discovery
Revenues:
Total revenues	14,215	11,930	24,950	15,113
Cost of revenues:
Total cost of revenues	$ 15,572	$ 8,832	$ 30,477	$ 18,564